Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 108 от 222

Recruiting Phase 3

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Chronic Kidney Disease and Hypertension

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Начало: 03.03.2025 Край: 18.12.2029 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +38 AstraZeneca NCT06742723

Recruiting Phase 2

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Non-small Cell Lung Cancer

This is a Phase II, multisite, open-label study consisting of two parts in participants with advanced/metastatic Non-small Cell Lung Cancer (NSCLC) which progressed after a first-line chemoimmunotherapy to evaluate the combination of pumitamig (also known as BNT327, BMS-986545 or PM8002) with standard of care. Part 1 is a safety run-in with pumitamig (Dose 1 or Dose 2) plus docetaxel and will include up to 12 participants in total to be treated in Part 1A and 1B sequentially. Part 2 is a dose expansion at the deemed safe dose of pumitamig plus docetaxel and will include up to 54 participants.

Начало: 03.03.2025 Край: 01.10.2028 Възраст: от 18 г. Treatment

Australia, South Korea, Spain +3 BioNTech SE NCT06841055

Recruiting Phase 3

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Psoriatic Arthritis

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.

Начало: 03.03.2025 Край: 28.01.2028 Възраст: от 18 г. Treatment

Belgium, Bulgaria, Chile +16 Takeda NCT06671483

Recruiting

Optimizing the Timing of rTMS to Enhance the Administration of Insomnia Treatment

Insomnia

Repetitive transcranial magnetic stimulation (rTMS) has shown to be a promising technique for improving insomnia symptoms and sleep quality. However, the impact of circadian rhythmicity on rTMS sessions and its potential influence on insomnia therapy remains unclear. Moreover, the effect of rTMS on objective sleep parameters is not fully established. The objective of this pilot study is to establish key feasibility and preliminary data that would be used for an R-level grant application focused on optimizing rTMS therapy for insomnia. The investigators will acquire feasibility data from ten adults with Insomnia disorder. Participants will receive ten sessions rTMS over two weeks, either in the morning or evening. Sleep parameters will be assessed before, during, and after completion of rTMS and brain cortical excitability will be collected before rTMS treatment. The investigators aim to 1) evaluate the impact of circadian timing of rTMS sessions on subjective and objective sleep outcomes, 2) assess the time course of improvements in sleep outcomes, and 3) examine the association between sleep outcomes and cortical excitability. The overarching goal of this work is to optimize rTMS therapy for insomnia by investigating the impact of circadian timing on rTMS sessions and assessing potential variations in subjective and objective measures of sleep.

Начало: 01.03.2025 Край: 30.09.2026 Възраст: 25–45 г.

United States Stanford University NCT06656533

Recruiting

EIM Via the Myolex mScan as an ALS Biomarker

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new therapeutic approaches. One critical aspect of all clinical trials is the need track to progression sensitively to identify the impact of therapy. Tools to track ALS progression must be convenient, objective, require minimal training, be easily standardized, cost-efficient, and have the potential to be applied effectively at home. There has been a push to identify accurate, objective biomarkers of ALS progression. In this study, the investigators propose to use Electrical impedance myography (EIM) to evaluate the progression of the disease. Work has shown that the EIM 50 kilohertz (kHz) phase value from one or more muscles, followed sequentially, can serve as an effective overall biomarker for assessing the rate of ALS progression for a single person.

Начало: 01.03.2025 Край: 30.05.2027 Възраст: от 18 г.

United States Beth Israel Deaconess Medical Center NCT06491732

Recruiting

Spinal Cord Injury Neurorecovery Collaboration

Spinal Cord Injuries

SCINC is an adaptive design Master protocol that seeks to determine if there is "sufficient promise" of beneficial effect of treatment combinations to enhance motor recovery in pre-specified strata of people with a spinal cord injury.

Начало: 01.03.2025 Край: 31.12.2027 Възраст: от 18 г. Treatment

Australia University of Melbourne NCT06871254

Recruiting Phase 1

A Phase 1 Study of S-1117

Healthy Volunteer

This is the first-in-human study of S-1117 designed to provide safety, tolerability, pharmacokinetic, and pharmacodynamic data in healthy volunteers.

Начало: 01.03.2025 Край: 01.03.2026 Възраст: 18–65 г. Treatment

Australia Seismic Therapeutic AU Pty Ltd NCT06828393

Recruiting Phase 2

Study of Olutasidenib and Temozolomide in HGG

High Grade Glioma Astrocytoma Astrocytoma, Grade III Astrocytoma, Grade IV +15

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.

Начало: 01.03.2025 Край: 01.06.2035 Възраст: 12–39 г. Treatment

Australia, Canada, Germany +3 Rigel Pharmaceuticals NCT06161974

Recruiting Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

HER2-positive Gastric Cancer Gastroesophageal Junction Adenocarcinoma

This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to assess the contribution of each component in the experimental arm.

Начало: 01.03.2025 Край: 09.12.2030 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +24 AstraZeneca NCT06764875

Recruiting

Exploring the Health Benefits of Sauna Bathing

Blood Pressure

Cardiovascular disease (CVD) is the leading cause of mortality in Aotearoa New Zealand, with hypertension being a major risk factor that remains difficult to manage with medication. Finnish sauna bathing (FSB), a widely practiced form of heat therapy, has been linked to lower risks of CVD, stroke, and overall mortality. Traditionally, FSB is combined with cold water immersion (CWI), but the combined effects of these therapies remain under explored. While sauna research often focuses on physiological aspects, this study aims to take a holistic approach to understanding its impact on cardiovascular health.

Начало: 01.03.2025 Край: 01.07.2025 Възраст: 18–70 г. Prevention

New Zealand The Centre for Health NCT06875466

Recruiting

Epidural Electrical Stimulation in Spinal Cord Injury

Spinal Cord Injuries (SCI)

The goal of this clinical trial is to evaluate the safety and effectiveness of Epidural Electrical Stimulation (EES) in motor and sensory function Reconstruction in chronic spinal cord injury (SCI) patients classified as ASIA B-D. The main questions it aims to answer are: Does EES treatment significantly improve motor and sensory function in patients with SCI compared to baseline? Is EES a safe intervention for this patient population? Researchers will compare participants' motor function, sensory function, and quality of life assessments before EES implantation, immediately after activation of the device, and at 1, 3, and 6 months post-implantation to evaluate the longitudinal effects of EES. Participants will: Undergo surgical implantation of an EES device in the epidural space. Have the EES device activated and receive personalized stimulation parameter adjustments during follow-up visits. Complete regular motor and sensory function assessments using standardized protocols. Participate in structured rehabilitation training sessions while using the EES device. Report any adverse events and complete quality of life questionnaires at specified follow-up intervals.

Начало: 01.03.2025 Край: 31.12.2026 Възраст: 16–60 г.

China Second Affiliated Hospital, School of Medicine, Zhejian NCT07105878

Recruiting

Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques

Lung Cancer, Non-Small Cell

The goal of this multicenter observational study is to evaluate the long-term survival and perioperative outcomes of sleeve lobectomy in robotic-assisted thoracic surgery (RATS) for patients with central lung cancer when compared with video-assisted thoracic surgery (VATS) approach, both of which have been already applied to these patients in minimally invasive surgical techniques as part of their regular medical care recently. The main question it aims to answer is: Are RATS sleeve lobectomy associated with similar or even better long-term survival and perioperative outcomes for patients with central lung cancer when compared with the VATS approach?

Начало: 01.03.2025 Край: 31.12.2027 Възраст: от 18 г.

China Second Affiliated Hospital, School of Medicine, Zhejian NCT06687408

Recruiting Phase 2

Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ

Gastric Adenocarcinoma Gastro-esophageal Junction Adenocarcinoma

This study is a single-arm, prospective, phase II clinical trial. The patients are diagnosed with resectable locally advanced (cT3-4N+M0) gastric adenocarcinoma and esophageal gastric adenocarcinoma that had not been treated before. After signing the informed consent form, patients will be screened for the study treatment of Adebrelimab combined with AOS. After 2 cycles of treatment, MDT assessments before surgery will be carried out. Patients with no disease progression will receive one more cycle of treatment before surgery. For patients who have undergone radical surgery, they will continue to receive 3 cycles of the immunochemotherapy after the operation (a total of 6 cycles of combined treatment before and after surgery), followed by Adebrelimab single treatment for up to a year (16 cycles). Patients whose disease progressed that can not be surgically removed after preoperative treatment will be treated by the oncology physicians according to clinical routines.

Начало: 28.02.2025 Край: 31.12.2027 Възраст: 18–75 г.

China Cancer Institute and Hospital, Chinese Academy of Medic NCT06808971

Recruiting Phase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Schizophrenia

Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

Начало: 28.02.2025 Край: 29.10.2026 Възраст: 18–65 г.

Japan, United States Otsuka Pharmaceutical Development & Commercialization, NCT06894212

Recruiting Phase 3

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Hidradenitis Suppurativa (HS)

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Начало: 28.02.2025 Край: 28.02.2028 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +16 Incyte Corporation NCT06855498

Recruiting Phase 2

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

Primary Myelofibrosis Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.

Начало: 28.02.2025 Край: 17.03.2028 Възраст: от 18 г.

Canada, France, Germany +3 GlaxoSmithKline NCT06517875

Recruiting Phase 1

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Solid Tumors EGFR Exon 20 Insertion Mutations NSCLC EGFR-mutated NSCLC

The purpose of this study is to establish the recommended phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-114 in combination with subcutaneous (SC) amivantamab in patients with advanced or metastatic NSCLC harboring an EGFR exon 20 insertion mutation.

Начало: 27.02.2025 Край: 01.12.2027 Възраст: от 18 г. Treatment

Australia, Canada, United States ORIC Pharmaceuticals NCT06816992

Recruiting Phase 1

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

Atopic Dermatitis

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Начало: 27.02.2025 Край: 06.02.2027 Възраст: 18–65 г. Treatment

Australia, New Zealand, United States Bambusa Therapeutics NCT06808477

Recruiting Phase 1/2

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Small Cell Lung Cancer

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to a specific target on cancer cells and delivers treatment to destroy those cells. Durvalumab is a different type of immunotherapy that also destroys cancer cells. Researchers want to know if giving gocatamig, I-DXd, and gocatamig with I-DXd or durvalumab can treat SCLC that did not respond or stopped responding to a prior treatment. The goals of this study are to learn: * If gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab are safe and well tolerated * If people who receive gocatamig alone, I-DXd alone, and gocatamig with I-DXd or durvalumab have their SCLC get smaller or go away

Начало: 27.02.2025 Край: 17.01.2030 Възраст: от 18 г. Treatment

Argentina, Australia, Chile +9 Merck Sharp & Dohme LLC NCT06780137

Recruiting Phase 3

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Immune Thrombocytopenic Purpura (ITP)

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).

Начало: 27.02.2025 Край: 28.12.2027 Възраст: от 18 г. Treatment

Australia, Bulgaria, China +13 Takeda NCT06722235

1 … 106 107 108 109 110 … 222